Foley & Lardner LLP recently released “Antibody Drug Conjugates Keep Growing: What You Need to Know,” a guide that answers many business and legal questions about the rapid expansion of this area of technology.
Licensing deals for antibody drug conjugates (ADCs), a class of chemotherapy medicines used in the treatment of cancers, are on the rise and worldwide ADCs sales are projected to reach US$20-30 billion per year in the near future. These drugs combine an antibody and cancer treating drug to minimize the impact of chemotherapy on healthy tissue, while maximizing their impact on the cancer, to reduce the overall negative impact on a patient.
Although ADCs have been used for more than two decades, continued development of the technology has given regulators, pharmaceutical companies, and doctors more confidence in the clinical efficacy of these treatments, but has also raised more questions.
Companies now need to know how to navigate a myriad of concerns related to ADCs/antibody therapeutics, including deals and licensing requirements, patent/IP challenges, and issues related to clinical trials, FDA/regulations, and litigation.
Companies touching this space should keep current on the progresses being made and how their businesses may be affected.
This guide unpacks the most pertinent questions and issues, with articles including:• Antibody Drug Conjugates: An FDA Perspective
• Strategies For Patenting Antibody-Drug Conjugate Inventions
• Deals and Licensing for Antibody-Drug Conjugates
• Antibody-Drug Conjugate Litigation
• Clinical Trial Issues for Antibody Drug Conjugates/Antibody Therapeutics
Foley &?Lardner’s guide is available online at www.foley.com/insights/publications/2024/12/antibody-drug-conjugates-growing-need-know.
Licensing deals for antibody drug conjugates (ADCs), a class of chemotherapy medicines used in the treatment of cancers, are on the rise and worldwide ADCs sales are projected to reach US$20-30 billion per year in the near future. These drugs combine an antibody and cancer treating drug to minimize the impact of chemotherapy on healthy tissue, while maximizing their impact on the cancer, to reduce the overall negative impact on a patient.
Although ADCs have been used for more than two decades, continued development of the technology has given regulators, pharmaceutical companies, and doctors more confidence in the clinical efficacy of these treatments, but has also raised more questions.
Companies now need to know how to navigate a myriad of concerns related to ADCs/antibody therapeutics, including deals and licensing requirements, patent/IP challenges, and issues related to clinical trials, FDA/regulations, and litigation.
Companies touching this space should keep current on the progresses being made and how their businesses may be affected.
This guide unpacks the most pertinent questions and issues, with articles including:• Antibody Drug Conjugates: An FDA Perspective
• Strategies For Patenting Antibody-Drug Conjugate Inventions
• Deals and Licensing for Antibody-Drug Conjugates
• Antibody-Drug Conjugate Litigation
• Clinical Trial Issues for Antibody Drug Conjugates/Antibody Therapeutics
Foley &?Lardner’s guide is available online at www.foley.com/insights/publications/2024/12/antibody-drug-conjugates-growing-need-know.
––––––––––––––––––––
Subscribe to the Legal News!
https://legalnews.com/Home/Subscription
Full access to public notices, articles, columns, archives, statistics, calendar and more
Day Pass Only $4.95!
One-County $80/year
Three-County & Full Pass also available
